At its final monthly meeting in London, the European Medicines Agency’s drug evaluation committee, the CHMP, gave the all-clear to all eight of the new drugs that were up for an opinion on EU marketing approval.
EU CHMP Backs Three Conditional Approvals & Several Treatment Firsts
Akcea’s Waylivra, Portola’s Ondexxya, BioMarin’s Palynziq, AbbVie’s Skyrizi and Pfizer’s Lorviqua are among new drugs to receive a positive opinion from the EU’s CHMP at its latest monthly meeting.
